ELEVATING tomorrow

Navigating Mortality Risk: Strategic Intelligence for Business Impact







Julianne Callaway

VP & Senior Actuary,
Strategic Research

RGA



Sara Goldberg

VP & Actuary,
U.S. Individual Markets

RGA





Limitations and Disclosures

The information contained in this this presentation is for educational purposes only, is confidential and may not be distributed, disclosed, copied or otherwise furnished to any additional party without the prior written consent of RGA. Nothing included in this presentation may be used in any filing with any public body, such as but not limited to the Securities and Exchange Commission (SEC) or state insurance department without prior written consent from RGA. Any distribution of this presentation must be in its entirety.

Statistics in this presentation rely on data provided to RGA. RGA did not perform independent audits of the data, although RGA did review the data for general reasonableness and consistency. The information used comes from a variety of companies with unique areas of practice, target markets, distribution methods, etc., and as such should not be deemed directly applicable to any single company or necessarily representative of the insurance industry as a whole. The presented information is intended to be valid as of the date it has been prepared. Its future validity depends on the further development of market events, regulations, and standards of practice.

Any results or conclusions presented in this presentation are not meant to substitute RGA's actuarial judgment for that of attendees. This presentation is not intended to contain material that represents an actuarial opinion.

RGA, its directors, officers and employees disclaim liability for any loss or damage arising or resulting from any errors or omissions in any information contained herein.





Outline of topics



Substance use



Mental health



Emerging mortality topics






Backdrop on mortality improvement: trends and drivers

Recent *positive* drivers

- Advances in treatments and therapeutics
- Smoking cessation / anti-smoking efforts
- Mostly declining cancer incidence coupled with better outcomes for those diagnosed and earlier screening

Recent adverse drivers

- Metabolic trends, especially type-2 diabetes
- External causes (suicides, opioids, etc.)
- ... and the COVID-19 pandemic








Cause of death shifts (55-year-old male)

Major improvements from cancer and cardiovascular.

What can we expect going forward?




Recent years have experienced deterioration in some historically less material drivers:

- Diabetes (-1%)
- Overdoses (-10%)
- Suicides (-1%)






U.S. female mortality trend heatmap







... Strategic intelligence?








Relevance to various stakeholders

- C-suite and investors
- ERM
- Actuaries
- Underwriters
- Product development
- Claims
- Reinsurance department










Overdose and substance use





Drug overdose deaths were increasing until recently




- Drug overdose deaths increased from about 30,000 in 2005 to nearly 108,000 in 2022.
- Overdose deaths began to decline beginning in 2023 through 2024 (provisional).





Insured substance-related mortality increased until 2021

Similar to the U.S. general population, a decline began in 2022 and continued in 2023









Potential drivers

Drivers are complex and rapidly changing, making it difficult to gauge trajectory



- Access to treatment
- More awareness of risks
- Various programs


- Polysubstance use / drug contamination
- More potent substances







Drug overdose rates by educational attainment




Demographic groups with higher overdose rates

- Lower education levels
- Males
- Ages 25-64
- Never-married individuals
- Construction-related occupations






For university-educated individuals, alcohol-induced deaths are now more prevalent than drug overdose deaths








Alcohol-induced deaths impact older ages





At the start of the COVID-19 pandemic, alcohol consumption increased up to 25%

Multiple diseases linked to alcohol consumption

- Cardiovascular disease
- Liver disease
- Gastrointestinal complications
- Certain cancers, such as colon, liver, and breast





There are many potential clues of substance use disorder

Behavior history

- Trauma
- Mental illness
- Extended sick leave
- Accidents

Medical records

- Hypertension
- Palpitations
- Gout
- Gastrointestinal issues
- Liver function test abnormalities

Prescription history

- Number of prescriptions
- Number of prescribers
- Duration of prescriptions
- Frequency of renewals

"It is important for underwriters to be trained to read between the lines and notice medical, social, and behavioral clues that may indicate a potential substance use disorder, especially given the current societal trends in drug use."

- Dr. Georgiana Willwerth, VP & Medical Director, RGA






Comparison of mortality rates by face amount

Experience is different for suicide and drug and alcohol abuse


Policies with higher face amounts have lower substance-related mortality, but higher suicide risk

Mortality Rates by Face Amount 2023 - Insured Population










Mental health





Mental illness is a comorbidity with substance use disorder



Various potential reasons

- Common risk factors
 (trauma, adverse social environment, genetics)
- Mental illness can lead to drug use for symptoms
- Benzodiazepine prescription for anxiety
- Substance use can worsen mental disorders


Mental health diagnoses for ages 35-44 have increased from 31% to 45% from 2019 to 2023.





Mortality for people with mental illness

Proprietary medical claims database to study mental health conditions



Elevated mortality risk for mental illness

- Male relative mortality higher in most ages for depression
- We also looked at bipolar and anxiety disorders
 - Bipolar disorder has relatively higher mortality impact than depression
 - Anxiety disorder is
 associated with higher
 mortality, but not as high
 as depression





Mental health and physical health are fundamentally linked



People with depression twice as likely to have poor health status

People with mood disorders are at elevated risk of developing several medical conditions

- Circulatory
- Pulmonary
- Endocrine
- Musculoskeletal
- Gastrointestinal
- Urogenital






Source: https://www.nejm.org/doi/full/10.1056/nejmoa1915784
Source: https://www.soa.org/49915d/globalassets/assets/files/resources/research-report/2025/2025-05-mhu.pdf

Mental health and obesity

Importance of Mental Health Issues on Obesity



- Very important role
- No role


- Somewhat important role Not very important role
- Note sure

76% of YouGov survey respondents identified mental health issues as an important contributor to obesity





Growing recognition of mental healthcare needs



85%

Reported mental health as a priority

57%

Reported additional demand for mental health-related products and services*

*in the last 2 years


RGA is working with partners around the world to better understand the mental health landscape.

How is the industry helping to bridge the gap in mental health?

Find out more by downloading the report.







Emerging mortality topics







Obesity trends

Underwriting provides protection from relatively higher all-cause mortality at higher BMIs


All-cause mortality increases as BMI increases





Steady increase in prevalence. Have we rounded the bend?

Obesity prevalence among U.S. adults 1999-2023



28.500 301.501 302.504 305.506 301.508 308.5010 301.5012 3014 3015.5016 301.502


Source: RGA analysis of NHIS data, 1987-2015. Multivariate model adjusts for age, sex, smoking, disease history, health status and income.





Health risks for those who are overweight / obese

Deaths related to obesity increased nearly 50% in the past 20 years



Obesity-related diseases

- High blood pressure
- High triglyceride levels
- Coronary heart disease
- Stroke
- Cancer
- Type-2 diabetes
- Osteoarthritis
- Sleep apnea
- Respiratory problems






Weight loss methods are largely unchanged

43% of American adults say they are overweight, and 55% would like to lose weight

Share of U.S. adults who were interested in select weight loss methods 2023



- 30% of U.S. adults say they have lost a significant amount of weight in the past two years.
- 4% used weight-loss medication for support.
- 25% use a fitness tracker or app.







Exercise reduces all-cause mortality

Impacts vary slightly for obese and non-obese populations

All-cause mortality hazard ratios by total weekly exercise duration, excluding those unable to exercise









1.00

Key findings from our study of the impact of exercise on an obese population



Exercise improves mortality experience for the obese population



Vigorous exercise shows additional mortality benefits compared to moderate exercise



Mortality benefits of exercise are slightly smaller for the obese population than for the non-obese population



Impacts of exercise increase with age






Climate risk

Average temperature

Suboptimal temperatures on both ends of the spectrum: a tale of two cities








Climate risk

Air pollution

- Key sources of air pollution in relation to its impact on mortality are fine particulate matter (PM2.5), nitrogen dioxide (NO2) and ozone
- The U.S. has made great strides on these since 1980. Will this continue?








Climate risk

Enter wildfire risk ...

- Wildfire pollutants (PM2.5 and beyond) up to 10x more potent than chemical composition of traditional air pollutants
- Air quality knows no boundaries
- Long-term effects still emerging ->
 can we think of this as we have
 accumulated pack-years?



Cumulatively by 2050, climate change could lead to an extra 14.5 million deaths worldwide under a "middle of the road" greenhouse gas emissions scenario






What's on the horizon?

Headwinds	Tailwinds
Slowing cardiovascular improvement	Genetics and all "-omics"
Obesity, diabetes, physical inactivity	Precision medicine – next gen CV therapies, biometric monitoring (PPG tech)
Cognitive / neurodegenerative diseases	Novel obesity and diabetes treatments – GLP-1 RA +++, reversibility of DM-2, impact on CVD
Infectious diseases	Cancer – prevention, early detection / MCED, personalized treatment, recurrence surveillance
Economics / population demographics	mRNA tech and universal vaccines including influenza
Climate change / environment	AI/GPT, machine learning - clinical medicine, research
What's the next opioid epidemic / vaping	Advanced therapeutics – Al driven drug and protein development, Alzheimer's disease prevention/treatment
Deaths of despair	Microbiome – all aspects of health
Public health and health care delivery	Regenerative medicine
Science "under the microscope"	Anti-ageing therapies – stem-cell rejuvenation and beyond







Call to action





Call to action for various stakeholders


- C-suite and investors
- ERM
- Actuaries
- Underwriters
- Product development
- Claims
- Reinsurance department







Share your feedback in the conference app



Agenda Option

